Grant: Discovery Grants Program - Individual
McMaster University
$50,000.00
Investigating hybrid physics-based intelligent quality assurance systems in continuous drug manufacturing
FY 2023-24
Summary
Drug availability is an urgent global challenge identified by the United Nations as part of a Sustainable Development Goal (SDG) on Wellbeing. In Canada, availability is closely associated with drug cost, which is very noticeable with newer therapeutics like those for cancer treatments, that are priced well beyond what many drug plans and healthcare providers can afford. Newer methods of producing drugs need developing to tackle the causes for the rising price tag on drugs, and one key area that both industry and academic researchers have focused their attention is manufacturing. Once this industry was completely dependent upon inefficient batch unit operations, but recently there has been strong demand to transition to continuous operations, replacing these slower, more wasteful and lower output methods of production. Calls for this switch are coming from regulators as well as from the public and within the industry. Twin-screw granulation (TSG) has matured as a continuous manufacturing technology to replace batch methods for creating solid oral drug forms like tablets. All major pharmaceutical companies now have internal groups developing TSG for upcoming drug production but current methods to address quality assurance monitoring, known as Quality by Design (QbD), in TSG have not been well received by regulatory leaders and this challenge needs to be urgently addressed. For continuous methods to retain their value as faster producers of high quality drugs, real-time assessment is required but regulators also want intelligent control present so that shifts in ingredients or the process do not equate with substantial drug waste (which is a significant contributor to a drug's price tag). The PI's group has been developing TSG for over a decade, forged many relationships with pharmaceutical companies, and recently created new inline monitoring technology to quantify the granulated mass being continuously created. Our roadmap to creating TSG as a viable manufacturing method has led us to this point, where it is now time, with all the tools in place and a vast library of granulation data accumulated, to tackle this final major hurdle. This research program envisions three main objectives and one transition objective, each led by a graduate student, to add a new sensor for assessing the quality of powder feed streams; to create a physics-based model serving to interpret a wide range of sensory data and identify causes for deviating product descriptors; to create a hybrid model based on artificial intelligence systems combined with the physics-based module to fully satisfy the real-time decision-making control system envisioned for QbD by global regulatory bodies; to implement a control system based on the hybrid model and begin the necessary validation of this process tool. This hybrid of physics-based and data-driven modeling will aid in the lowering of drug costs by allowing the proper implementation of continuous manufacturing.
Program
Discovery Grants Program - Individual
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
RGPIN-2023-04751
Name nom
Thompson, Michael
Department département
Dept of Chemical Engineering
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2023
Award amount
50000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1511
Committee name en
Materials and Chemical Engineering
Committee name fr
Génie chimique et des matériaux
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
1604
Research subject group en
Industrial engineering
Research subject group fr
Manufacturing
Research subject en
Génie industriel
Research subject fr
Fabrication
Application title
Investigating hybrid physics-based intelligent quality assurance systems in continuous drug manufacturing
Keyword
continuous materials processes; granulation; machine learning; pharmaceutical manufacturing; physics-based modelling; population balance model; process analytical technology; quality assurance; quality by design; twin screw granulator
Application summary
Drug availability is an urgent global challenge identified by the United Nations as part of a Sustainable Development Goal (SDG) on Wellbeing. In Canada, availability is closely associated with drug cost, which is very noticeable with newer therapeutics like those for cancer treatments, that are priced well beyond what many drug plans and healthcare providers can afford. Newer methods of producing drugs need developing to tackle the causes for the rising price tag on drugs, and one key area that both industry and academic researchers have focused their attention is manufacturing. Once this industry was completely dependent upon inefficient batch unit operations, but recently there has been strong demand to transition to continuous operations, replacing these slower, more wasteful and lower output methods of production. Calls for this switch are coming from regulators as well as from the public and within the industry. Twin-screw granulation (TSG) has matured as a continuous manufacturing technology to replace batch methods for creating solid oral drug forms like tablets. All major pharmaceutical companies now have internal groups developing TSG for upcoming drug production but current methods to address quality assurance monitoring, known as Quality by Design (QbD), in TSG have not been well received by regulatory leaders and this challenge needs to be urgently addressed. For continuous methods to retain their value as faster producers of high quality drugs, real-time assessment is required but regulators also want intelligent control present so that shifts in ingredients or the process do not equate with substantial drug waste (which is a significant contributor to a drug's price tag). The PI's group has been developing TSG for over a decade, forged many relationships with pharmaceutical companies, and recently created new inline monitoring technology to quantify the granulated mass being continuously created. Our roadmap to creating TSG as a viable manufacturing method has led us to this point, where it is now time, with all the tools in place and a vast library of granulation data accumulated, to tackle this final major hurdle. This research program envisions three main objectives and one transition objective, each led by a graduate student, to add a new sensor for assessing the quality of powder feed streams; to create a physics-based model serving to interpret a wide range of sensory data and identify causes for deviating product descriptors; to create a hybrid model based on artificial intelligence systems combined with the physics-based module to fully satisfy the real-time decision-making control system envisioned for QbD by global regulatory bodies; to implement a control system based on the hybrid model and begin the necessary validation of this process tool. This hybrid of physics-based and data-driven modeling will aid in the lowering of drug costs by allowing the proper implementation of continuous manufacturing.